Rescue therapy for lamivudine-resistant chronic hepatitis B: Adefovir monotherapy, adefovir plus lamivudine or entecavir combination therapy

Internal Medicine

Volumn 51, Issue 12, 2012, Pages 1509-1515

  Ha, Minghao ^a   Zhang, Guotong ^a   Diao, Shu ^a   Lin, Mingfang ^a   Wu, Jianqiu ^a   Sun, Liping ^a   She, Huiyuan ^a   Shen, Lihui ^a   Huang, Chunhong ^a   Shen, Wenjuan ^a   Huang, Zhongming ^a  

^a Shanghai 7th People's Hospital   (China)

Author keywords

HBV; Rescue therapy; Viral breakthrough

Indexed keywords

ADEFOVIR; ALANINE AMINOTRANSFERASE; ALBUMIN; ASPARTATE AMINOTRANSFERASE; BILIRUBIN; ENTECAVIR; HEPATITIS B (E) ANTIBODY; HEPATITIS B SURFACE ANTIGEN; HEPATITIS B(E) ANTIGEN; LAMIVUDINE; UNCLASSIFIED DRUG; VIRUS DNA;

ADD ON THERAPY; ADULT; ARTICLE; COMBINATION CHEMOTHERAPY; ENZYME IMMUNOASSAY; FEMALE; FOLLOW UP; GENE MUTATION; HEPATITIS; HEPATITIS B; HEPATITIS B VIRUS; HUMAN; MAJOR CLINICAL STUDY; MALE; MONOTHERAPY; PROTHROMBIN TIME; REAL TIME POLYMERASE CHAIN REACTION; RESTRICTION FRAGMENT MASS POLYMORPHISM; TREATMENT RESPONSE;

ADENINE; ADULT; ANTIVIRAL AGENTS; DNA, VIRAL; DRUG RESISTANCE, VIRAL; DRUG THERAPY, COMBINATION; FEMALE; GUANINE; HEPATITIS B VIRUS; HEPATITIS B, CHRONIC; HUMANS; LAMIVUDINE; MALE; MIDDLE AGED; MUTATION; PHOSPHONIC ACIDS; TIME FACTORS;

EID: 84862983848     PISSN: 09182918     EISSN: 13497235     Source Type: Journal    
DOI: 10.2169/internalmedicine.51.7329     Document Type: Article

References (33)

1. Lee W. Hepatitis B virus infection. N Engl J Med 337: 1733-1745, 1997.
2. Liaw YF, Sung JJ, Chow WC, et al. Lamivudine for patients with chronic hepatitis B and advanced liver disease. N Engl J Med 351: 1521-1531, 2004.
3. Yuen MF, Seto WK, Chow DH, et al. Long-term lamivudine therapy reduces the risk of long-term complications of chronic hepatitis B infection even in patients without advanced disease. Antivir Ther 16: 1295-1303, 2007.
4. Lok AS, McMahon BJ. Chronic hepatitis B. Hepatology 45: 507-539, 2007.
5. Yang H, Qi X, Sabogal A, Miller M, Xiong S, Delaney WE IV. Cross resistance testing of next-generation nucleoside and nucleo-tide analogues against lamivudine-resistant HBV. Antivir Ther 10: 625-633, 2005.
6. Fung SK, Chae HB, Fontana RJ, et al. Virologic response and resistance to adefovir in patients with chronic hepatitis B. J. Hepatol 44: 283-290, 2006.
7. Yeon JE, Yoo W, Hong SP, et al. Resistance to adefovir dipivoxilin lamivudine resistant chronic hepatitis B patients treated with adefovir dipivoxil. Gut 55: 1488-1495, 2006.
8. Lee YS, Suh DJ, Lim YS, et al. Increased risk of adefovir resistance in patients with lamivudine-resistant chronic hepatitis B after 48 weeks of adefovir dipivoxil monotherapy. Hepatology 43: 1385-1391, 2006.
9. Lampertico P, Vigano M, Manenti E, Iavarone M, Lunghi G, Colombo M. Adefovir rapidly suppresses hepatitis B in HBeAg-negative patients developing genotypic resistance to lamivudine. Hepatology 42: 1414-1419, 2005.
10. Chang TT, Gish RG, Hadziyannis SJ, et al. A dose-ranging study of the efficacy and tolerability of entecavir in Lamivudine refractory chronic hepatitis B patients. Gastroenterology 129: 1198-1209, 2005.
11. Sherman M, Yurdaydin C, Simsek H, et al. Entecavir therapy for lamivudine-refractory chronic hepatitis B: Improved virologic, biochemical, and serology outcomes through 96 weeks. Hepatology 48: 99-108, 2008.
12. Tenney DJ, Rose RE, Baldick CJ, et al. Longterm monitoring shows hepatitis B virus resistance to entecavir in nucleoside-naïve patients is rare through 5 years of therapy. Hepatology 49: 1503-1514, 2009.
13. Lok AS, McMahon BJ. Chronic hepatitis B: Update. Hepatology 50: 661-662, 2009.
14. Holomn J, Glasa J. EASL clinical practice guidelines. J Hepatol 51: 821-822, 2009.
15. Marcellin P, Heathcote EJ, Buti M, et al. Tenofovir disoproxil fu-marate versus adefovir dipivoxil for chronic hepatitis B. N Engl J Med 359: 2442-2455, 2008.
16. Shim JH, Suh DJ, Kim KM, et al. Efficacy of entecavir in patients with chronic hepatitis B resistant to both lamivudine and adefovir or to lamivudine alone. Hepatology 50: 1064-1071, 2009.
17. Ghany MG, Doo EC. Antiviral resistance and hepatitis B therapy. Hepatology 49: S174-S184, 2009.
18. Zoulim F, Buti M, Lok AS. Antiviral-resistant hepatitis B virus: can we prevent this monster from growing? J Viral Hepat 14: 29-36, 2007.
19. Gaia S, Barbon V, Smedile A, et al. Lamivudine-resistant chronic hepatitis B: an observational study on adefovir in monotherapy or in combination with lamivudine. J Hepatol 48: 540-547, 2008.
20. Hadziyannis SJ, Tassopoulos NC, Heathcote EJ, et al. Long-term therapy with adefovir dipivoxil for HBeAg-negative chronic hepatitis B for up to 5 years. Gastroenterology 131: 1743-1751, 2006.
21. Keeffe EB, Dieterich DT, Han SH, et al. A treatment algorithm for the management of chronic hepatitis B virus infection in the United States: 2008 update. Clin Gastroenterol Hepatol 6: 1315-1341, 2008.
22. Yim HJ, Hussain M, Liu Y, Wong SN, Fung SK, Lok AS. Evolution of multi-drug resistant hepatitis B virus during sequential therapy. Hepatology 44: 703-712, 2006.
23. Villet S, Pichoud C, Billioud G, et al. Impact of hepatitis B virus rtA181V/T mutants on hepatitis B treatment failure. J Hepatol 48: 747-755, 2008.
24. Sheng YJ, Liu JY, Tong SW, et al. Lamivudine plus adefovir combination therapy versus entecavir monotherapy for lamivudine-resistant chronic hepatitis B: a systematic review and meta-analysis. Virol J 8: 393-398, 2011.
25. Kim HJ, Park JH, Park DI, et al. Rescue therapy for lamivudine-resistant chronic hepatitis B: comparison between entecavir 1.0 mg monotherapy, adefovir monotherapy and adefovir add-on lami-vudine combination therapy. J Gastroenterol Hepatol 25: 1374-1380, 2010.
26. Peters MG, Hann HW, Martin P, et al. Adefovir dipivoxil alone or in combination with lamivudine in patients with lamivudine-resistant chronic hepatitis B. Gastroenterology 126: 91-101, 2004.
27. Gallego A, Sheldon J, Garcia-Samaniego J, et al. Evaluation of initial virological response to adefovir and development of adefovir-resistant mutations in patients with chronic hepatitis B. J Viral Hepatol 15: 392-398, 2008.
28. Yatsuji H, Suzuki F, Sezaki H, et al. Low risk of adefovir resistance in lamivudine-resistant chronic hepatitis B patients treated with adefovir plus lamivudine combination therapy: two-year follow-up. J. Hepatol 48: 923-931, 2008.
29. Tenney DJ, Rose RE, Baldick CJ, et al. Two-year assessment of entecavir resistance in Lamivudine-refractory hepatitis B virus patients reveals different clinical outcomes depending on the resistance substitutions present. Antimicrob Agents Chemother 51: 902-911, 2007.
30. Rapti I, Dimou E, Mitsoula P, Hadziyannis SJ. Adding-on versus switching-to adefovir therapy in lamivudine-resistant HBeAg-negative chronic hepatitis B. Hepatology 45: 307-313, 2007.
31. Villet S, Pichoud C, Billioud G, et al. Impact of hepatitis B virus rtA181V/T mutants on hepatitis B treatment failure. J Hepatol 48: 747-755, 2008.
32. Qi X, Xiong S, Yang H, Miller M, Delaney WE. In vitro susceptibility of adefovir-associated hepatitis B virus polymerase mutations to other antiviral agents. Antivir Ther 12: 355-362, 2007.
33. Reijnders JG, Pas SD, Schutten M, de Man RA, Janssen HL. Entecavir shows limited efficacy in HBeAg-positive hepatitis B patients with a partial virologic response to adefovir therapy. J Hepatol 50: 674-683, 2009.